Neoadjuvant immunotherapy improves outcomes in high-risk melanoma patients.

Published Date: 02 Mar 2023

High-risk melanoma patients who received the drug pembrolizumab before or after surgery to remove the cancer had a higher risk of developing melanoma than those who did not have a similar condition that eliminated cancer cells.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

An FDA panel supports the use of CAR T-cell therapy earlier in the treatment of multiple myeloma.

2.

Toxic fungus from King Tutankhamun's tomb yields cancer-fighting compounds—new study

3.

Patients with head and neck cancer who cannot receive cisplatin now have new hope.

4.

It Is Cancer in Kate Middleton.

5.

Patients With Melanoma Brain Mets May Fare Better With RT Before Immunotherapy


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot